Form 8-K - Current report:
SEC Accession No. 0001193125-23-098482
Filing Date
2023-04-12
Accepted
2023-04-12 08:06:00
Documents
13
Period of Report
2023-04-11
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d460755d8k.htm   iXBRL 8-K 23180
5 GRAPHIC g460755g0412042719217.jpg GRAPHIC 2369
  Complete submission text file 0001193125-23-098482.txt   151698

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vrdn-20230411.xsd EX-101.SCH 2889
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE vrdn-20230411_lab.xml EX-101.LAB 17994
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vrdn-20230411_pre.xml EX-101.PRE 11287
7 EXTRACTED XBRL INSTANCE DOCUMENT d460755d8k_htm.xml XML 3396
Mailing Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453
Business Address 203 CRESCENT STREET BLDG. 17, SUITE 102B WALTHAM MA 02453 617.272.4600
Viridian Therapeutics, Inc.\DE (Filer) CIK: 0001590750 (see all company filings)

IRS No.: 471187261 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36483 | Film No.: 23814659
SIC: 8071 Services-Medical Laboratories